Prof. Dai-Ming Fan is a foreign academician in the Institute of Medicine of the National Academies. Also, he is the academician and vice president of the Chinese Academy of Engineering, president of the Fourth Military Medical University, chief physician, a gastroenterology expert in China, director of the State Key Laboratory of Tumor Biology, an invited professor of the cheung kong scholars programme, and a chief scientist of the National Basic Research Program (973 Program). National High Technology Research and Development Program (863 Program), National Programs for Science and Technology Development, Key New Drug Creation and Development Program, Key Program of the National Natural Science Foundation, etc. Prof. Dai-Ming Fan has long been engaged in both the clinical and basic research of digestive diseases and malignant tumor, undertaking sever Groups assigned by the Natural Science Foundation of China.
Gastroenterology; tumor biology
Academician Yan Sun is an academician of the Chinese Engineering Academy, and one of the founders of Chinese internal medicine tumor. Also, he is the honorary dean of Guangzhou NanYang Tumor Hospital, the specialist of International Famous Clinical Oncology Internal Medicine, professor and doctoral tutor of Chinese Academy of Medical Sciences Cancer Hospital, the director of the National Antitumor Drug Clinical Trial Research Center, vice President of China Cancer Research Foundation, vice President of Asia Clinical Oncology Society, committee of the International Union of Cancer (UICC) Academic Affairs, committee of the World Health Organization Cancer Expert Advisory, and the general counsel of Global Cancer Express.
Dr. Miele completed his medical training in Italy and his graduate training at the Max-Planck Institute for Molecular Genetics in Berlin. He then completed a fellowship in Human Genetics at the NIH (NICHD). There, he developed: 1) pharmacologically active peptides from human uteroglobin/CC10; 2) novel expression vectors to produce native, clinical-grade disulfide-bonded human proteins and 3) an early version of PCR-ELISA to quantify normal and mutant DNA in patient blood. In 1994, he moved to FDA/CBER as a senior investigator in the Division of Monoclonal Antibodies and member of the Division of Clinical Trials Design and Analysis. He was eventually promoted Acting Chief, Laboratory of Cell Biology. Dr. Miele co-authored the 1997 Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products. At CBER, in 1994, he began working on the then recently discovered human Notch genes. Notch pathway genes control cell fate determination during normal development and adult life, and have major roles in tumor biology, angiogenesis and the immune system. In 1998, Dr. Miele moved to Loyola University's Cardinal Bernardin Cancer Center, where he discovered the anti-apoptotic activity of Notch1 in leukemia cells. At the same time, he created and oversaw a Molecular Pathology Core. In 2001, Dr. Miele moved to the University of Illinois at Chicago, as Program Director in the Cancer Center and Associate Professor of Biopharmaceutical Sciences. At UIC, Dr. Miele determined that Notch1 is necessary for Ras-induced transformation of human cells and is expressed in breast cancer. In 2005, he returned to Loyola, as a Full Professor, Breast Cancer Program Director and eventually, Associate Cancer Center Director for Translational Sciences. In 2009, Dr. Miele was named Director of the UMMC Cancer Institute and Ergon Professor of Medicine. He held that post until his move to LSUHSC. Dr. Miele’s work is devoted to: 1) studies of cancer stem cell-regulatory genes such as Notch, and identification of genetic circuitry mediating Notch signals in human tumors; 2) Correlation between GWAS data and transcriptome for cancer-associated genes; 3) Mechanism-based early clinical trials using genomic biomarkers as correlative endpoints and/or stratification variables. Dr. Miele has authored 195 publications in biomedical journals to date. He has served or serves on numerous grant review panels for NIH, NCI, NCATS, the DOD and foreign research funding agencies from Canada, the UK, Spain, Italy, The Netherlands and Singapore. He serves as Editor or Associate Editor of a number of biomedical journals, and has served as an advisor to several pharmaceutical and biotechnology companies.
Immunology; molecular medicine; breast cancer; prostate tumor
Dr. Chen has recieved his MS degree in Biochemical Pharmacology/Toxicology from Sun YatSen University China,MD degree from Guangdong Medical and Pharmaceutical College China, Ph D degree in Cancer Pharmacology from Kagoshima University School of Medicine Japan, Postdoctoral training at Kagoshima University Japan, another Postdoctoral training in the Department of Medical Oncology Fox Chase Cancer Center Philadelphia. He started his professional career as Assistant professor at St. John's University in 2004. After that he worked as Associate professor at St.John's University in 2008.His research effortsare enclosed in Cancer Pharmacology and Experimental Therapeutics especially focusing on cellular mechanisms of multidrug resistance MDR. He has been involved in the research of most of the multidrug resistance proteins MRPs and have published ~60 publications in peerreviewed Journals for the last 10 years. He teaches Biochemistry Pharmacology Oncology at St John's University. He is a reviewer of 33 journals including International Journals and an editorial board member of 10 journals.
Molecular and cellular pharmacology of anticancer drugs, such as drug resistance mechanisms and reversal of resistance study and new drug development; breast cancer; oral cancer
Dr. Datta is Professor and Director of Research in the Division of Hematology/Oncology. He is also leader of the Colon and Lung Cancer Basic Research Program. He serves as Research Scientist at the Veterans Affairs Medical Center. Dr. Datta majors in the mechanism of TGF-β signaling in Colorectal Cancer and Lung Cancer. Dr. Datta published his research results in some famous international journals such as Gastroenterology, Cancer Research, JBC and he also serves as the Reviewer for Cancer Research, Clinical Cancer Research, Neoplasia.
GI; liver cancers
Umberto Galderisi is Professor of Molecular Biology at the School of Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy, and Adjunct Professor, Sbarro Inst. for Cancer Research and Mol. Medicine, Temple Univ, Philadelphia, USA. He obtained his master degree in Biological Sciences, summa cum laude, University of Naples, Italy in 1987, he did his PhD in Department of Genetics, General and Molecular Biology, University of Naples, Italy in 1992. The major research interests include stem cells, cancer stem cells, senescence, apoptosis, cell cycle, oncogenes and oncosuppressors.
Stem cells, cancer stem cells, senescence, apoptosis, cell cycle, oncogenes, oncosuppressors
National Association of Italian Biologist.
ISSCR (International Society for Stem Cell Researches).
International Society for Cellular Therapy (ISCT).
ECSA (European Cellular Senescence Association).
Founder and President of Stem Cell Research Italy, scientific association of researchers involved in stem cell studies (www.stemcellitaly.org).
Dr. Gopal Kundu has obtained his Ph.D. in chemistry from Bose Institute, Kolkata, India (1989). He did his post-doctoral research work at the Cleveland Clinic Foundation, University of Colorado, University of Wyoming, and the National Institutes of Health from 1989 to 1998. He has performed work in the area of cardiovascular biology, inflammation and immunomodulation during that period. In 1998, he joined as Scientist-D at National Centre for Cell Science (NCCS), India and at present he is Scientist-G. His area of research at NCCS is tumor biology, regulation of gene expression, cell signaling, cancer stem cells, angiogenesis, cancer therapeutics, biomarker studies and nanomedicine. He has received several awards including Fellows Award for Research Excellence from NIH, USA; National Bioscience Award, Govt. of India; Shanti Swarup Bhatnagar Prize, Govt. of India; International Award in Oncology, Greece; International Young Investigator Award, USA and 7th National Grassroots Innovation Award, Rashtrapati Bhavan, India. He is Fellow of National Academy of Sciences and Indian Academy of Sciences. He has published 74 papers including Nature Medicine, Science, PNAS, Cancer Research, JBC, TCB, Oncogene, Nanomedicine etc and one US patent. He serves as Editorial Board Member of Current Molecular Medicine, Molecular Medicine Reports, The Open Cancer Journal and American Journal of Cancer Research.
Tumor biology; regulation of gene expression; angiogenesis; cancer stem cells; chemical biology and nanotechnology
Dr. Jian Jian Li received undergraduate training at Xian Medical College and obtained the Mater of Medicine degree 1984 at Fourth Military Medicine University, China. Awarded the UICC (International Union Against Cancer) Fellowship in 1988, he worked as Research Fellow in the Department of Radiation Oncology, University of California San Francisco (1988-90), earned his Ph.D. of Radiation Biology in 1994 at University of Iowa before training as Postdoctoral Fellow at National Cancer Institute, National Institutes of Health (1995-98). He started faculty position (Assistant, Associate Professor) at City of Hope Medical Center (1999-04), and Associate and Full Professor at Purdue University (2004-09). Since 2009 he is serving as Full Professor and Director of Translational Research at the Department of Radiation Oncology, University of California Davis School of Medicine and NCI-Designated Comprehensive Cancer Center. Dr. Li’s research is to reveal the mechanisms causing cancer therapy-resistance due to reprograming mitochondrial metabolism and repopulation of cancer stem cells. He has published >100 papers including Dev. Cell, Cancer Research, Clin. Cancer Research, Oncogene, JBC, Mol. Cancer Research, and was/is Associate Editor/Editorial Board Member for Cell Research, BMC Physics, Int. J. Radiation Biology, J. Cancer Metastasis and Treatment, PLOS ONE, Radiation Research, and member in many grant review panels including National Institutes of Health, Cancer Research United Kingdom, National Natural Science Foundation of China, Technology and Research (A*Star) of Singapore, and a reviewer for many scientific journals.
Cancer radioresistance, mitochondrial function, metabolism, cancer stem cells, therapeutic targets.
Yin-Yuan Mo is Professor in the Department of Pharmacology/Toxicology, Cancer Institute, at University of Mississippi Medical Center. His research interests are epigenetic regulation of genes involved in tumorigenesis and chemoresistance, cancer susceptibility due to alterations of microRNA expression, and lncRNA-mediated gene expression in cancer.
Epigenetic regulation of genes involved in tumorigenesis and chemoresistance; cancer susceptibility due to alterations of microrna expression; long non-coding rna-mediated gene expression in cancer
Dr. Nicolini graduated (summa cum laude) at School of Medicine, University of Pisa in 1974. He received postgraduate diplomas at University of Pisa in Internal Medicine (1980), Pneumology (1984), and Nuclear Medicine (1986). His research interests include breast and gastrointestinal cancer and their metastases, tumour markers, post-operative follow-up, physiopathology, immunology and immunotherapy of cancer, and thyroid tumours.
Malignant solid tumours; breast cancer; colorectal cancer and their metastases; tumour markers; post-operative follow-up; physiopathology; immunology and immunotherapy of cancer; thyroid tumours
Dr. Godefridus (Frits) J. Peters is a Dutch experimental oncologist, pharmacologist and biochemist, and is at the Laboratory Medical Oncology at the VU University Medical Center. The major research interests of Prof. Peters include all aspects of pharmacology of anticancer agents, with emphasis on antifolates, other antimetabolites, platinum analogs, taxanes, anti-signalling agents and third generation targeted-agents. Prof. Peters serves as Editorial Board member for more than 30 international journals. In addition, he is (co-)author of more than 600 publications and was invited as a chair/speaker at many international conferences.
Drug development, drug delivery, drug transport and metabolism, clinical pharmacology, pharmacokinetics and pharmacogenetics.
Dr. Schiemann is the Goodman-Blum Professor in Cancer Research within the Case Comprehensive Cancer Center at Case Western Reserve University; he is also the Leader of the Breast Cancer Program in Development. He received his PhD in Pharmacology from the University of Washington in 1996, followed by Postdoctoral training in Cancer Biology in the laboratory of Dr. Harvey F. Lodish at the Whitehead Institute for Biomedical Research/MIT from 1997-2001. He began his independent research career as an Assistant Professor at the National Jewish Medical and Research Center (Denver, CO) in 2001, and later as an Associate Professor of Pharmacology at the University of Colorado-Denver Anschutz Medical Campus (Aurora, CO) in 2006. His current research efforts center on elucidating the molecular mechanisms of breast cancer metastasis and metastatic latency/dormancy, as well as on determining how these events impact the behaviors of cancer stem cells.
Breast cancer development and metastatic progression; metastatic latency and/or dormancy; EMT programs; cancer stem cells; short and long noncoding RNAs; integrins and mechanotransduction; signal transduction; TGF-β biology.
Masayuki Watanabe, Japanese pediatrician. Diplomate Ministry Health Labor Welfare Japan, 1995. Member of Japan Society Perinatal Neonatal Medicine, Japanese Society Pediatrics Cardiology Cardiac Surgery, Japanese Society Pediatrics Allergy Clinical Immunology, Japan Pediatrics Society.
Gastroenterological cancer; gastric cancer; esophageal cancer; liver metastasis; colon cancer
Yaguang Xi serves as an Professor of LSU Health Sciences Center New Orleans, USA. In 2003, Dr. Xi earned his Ph.D. degree in cancer biology from the Peking University after he accomplished the medical training. His expertise covers molecular biology, cell biology, genomics, genetics, oncology, and bioinformatics. Currently, Dr. Xi focuses on characterizing micro-RNA biomarkers and validating their important roles in cancer development, tumor metastasis, chemotherapy, and prevention.Yaguang Xi is currently working in Oncologic Sciences, Mitchell Cancer Institute at the University of South Alabama. He has got many memberships in professional asociations like American Association for Cancer Research, American Society of Clinical Oncology, International Honor Society Beta Gamma Sigma. Also he has won many awards for his research works and for his teaching experience.His major projects are holding the grants from NIH.
Colorectal cancer; breast cancer metastasis
Prasad S Adusumilli has completed his M.B.B.S. at the age of 22 years from Guntur Medical College and postdoctoral studies from AIIMS, New Delhi, Southampton University, UK and from Memorial Sloan Kettering Cancer Center (MSKCC) and University of Pittsburgh, USA. He is now the Deputy Chief of Thoracic Surgery at the MSKCC and Member in Center for Cell Engineering at MSKCC. He has published more than 100 papers in reputed journals including JCO and JNCI. He is invited to be the Deputy Chief Editor for Molecular Therapy Oncolytics Journal (Nature Group Publication) serves as an editorial board member of PLOSOne.
Chemo immunotherapy for lung cancer/mesothelioma
Alexandre Arcaro is a group leader at Bern University Hospital. He graduated at the University of Lausanne and obtained a Ph.D. from the University of Fribourg. He was then a postdoc at the Ludwig Institute for Cancer Research, UCL and Lausanne Branch. He was then a lecturer at Imperial College London. Subsequently, he was a group leader at the University Children's Hospital Zurich.
Common tumors in children include leukemia; brain tumors and neuroblastoma
Dr. Rossana Berardi is Assistant Professor of Medicine & Surgery at the Clinic of Medical Oncology, University of Marche , AOU United Hospitals of Ancona , Italy. She achieved her degree in Medicine Surgery at the University of Ancona in July 1997. Dr. Rossana Berardi received Diploma in Ultrasound, released by the Italian Society for Ultrasound in Medicine and Biology (SIUMB) in 1998. She completed her postgraduate Diploma in Oncology at the Postgraduate School of Oncology, University of Ancona by 2001. Dr. Rossana Berardi has served on many review panels, has reviewed for many journals. Dr. Rossana Berardi has over 168 peer reviewed publications. Dr. Rossana Berardi research interests include Oncology, Immunology, Cancer Research, DnA damage & Repair.
Clinical and translational research on treatment of solid tumors and on prognostic factors; research on SIADH; prostate cancer; breast cancer; colon cancer; renal cancer; glioblastoma; liver cancer
I completed my medical education at Coimbatore Medical College, Dr. MGR Medical University, Tamil Nadu, India, prior to moving to the United States. I initially trained in Internal Medicine at Westchester Medical Center, New York Medical College and then at Stony Brook University, New York, before deciding to switch fields to Radiation Oncology. I completed Radiation Oncology residency at University of Louisville, Kentucky. I then underwent fellowship training at Massachusetts General Hospital, Harvard Medical School focusing on proton therapy. I am currently practicing as an Assistant Professor in Radiation Oncology at The James Comprehensive Cancer Center, The Ohio State University in Columbus, Ohio. My research interests and areas of practice includeCNS, Skull base and Head and Neck tumors.
Head and Neck tumors; skull base tumors; skin cancers
Dr. Chun Hei Antonio Cheung is an Assistant Professor of Pharmacology in the National Cheng Kung University College of Medicine in Taiwan. He graduated with a PhD degree from the University of Auckland in New Zealand, and subsequently undertook his post-doctoral studies in the National Health Research Institutes in Taiwan. He is member of various scientific societies including The Royal Society of New Zealand, American Association for Cancer Research, European Association for Cancer Research and Hong Kong Institution of Science. Dr. Cheung has published both research and review articles in international journals such as PLoS ONE, Molecular Cancer, Cancer Letters, Current Medicinal Chemistry, Investigational New Drugs, and Expert Opinion on Investigational Drugs. He is the guest/managing editor of the journal Frontiers in Bioscience.
Colon cancer; breast cancer; hepatic metastasis of colon cancer; prostate cancer; chemotherapy in breast and colon cancer
Dr. Ezharul H. Chowdhury is currently holding an Associate Professor position and a cluster leader of 'Biomedical Engineering' under Advanced Engineering Platform (AEP) at MONASH University (Sunway Campus). Prior to this appointment, he was a Senior Lecturer at International Medical University (IMU) since September 2008 and an independent Assistant Professor of Tokyo Institute of Technology (Tokyo Tech) as well as a Visiting Professor at Shizuoka Cancer Center Institute since 2006. He was awarded with 'Doctor of Engineering' in 2003 by Tokyo Tech where he also carried out a post-doctoral study and subsequently, served as a team leader. He has pioneered the development of a range of pH-sensitive inorganic nanoparticles as smart tools for efficient and targeted intracellular delivery of genetic materials, gene-silencing elements, proteins and classical anti-cancer drugs. He is currently applying this smart nanotechnology for the treatment of cancer, particularly breast carcinoma, and diabetes. His team is now conducting pre-clinical trials with some interesting nano-formulations of classical anti-cancer drugs, therapeutic gene(s) and anti-sense RNAs (siRNAs). His research team is thus one of the leading groups in the world, having original and unique contributions in this multidisciplinary field. Currently he is supervising 8 PhD students and 1 Master student. His research projects have so far been funded internally through institutional grants as well as externally by the Japanese Government's Ministry of Education, Culture, Sports, Science & Technology (MEXT), Japan Society for the Promotion of Science (JSPS), the Malaysian Ministry of Science, Technology and Innovation (MOSTI) and Ministry of Higher Education (MOHE). He works as editorial board members for 5 international journals. His outstanding contributions have so far produced over 65 publications in the international journals of high repute.
Biodegradable inorganic nanosized particles and utilizing them in the delivery of multiple therapeutics, such as gene, protein, antisense oligonucleotide or siRNA (Small interfering RNA) and conventional drugs; cervical cancer;lung cancer; breast cancer
Dr. Judy Crabtree is an Assistant Professor at Louisiana State University Health Sciences Center in New Orleans. She received her PhD from the University of Oklahoma and completed a postdoctoral study at the National Human Genome Research Institute in Bethesda, MD under the direction of Dr. Francis Collins. Dr. Crabtree worked in drug development at Wyeth Pharmaceuticals for 6 years before returning to academic science at LSUHSC. Dr. Crabtree’s research focuses on mechanisms of tumorigenesis in hormone-responsive and neuroendocrine-derived cancers. Specifically, ER+ breast cancer and neuroendocrine cancers of the endocrine pancreas, parathyroid and skin using a variety of in vitro and in vivo models to understand genetic, epigenetic and non-genetic contributions. The Crabtree laboratory studies the role of the histone demethylase protein RBP2/KDM5A pancreatic NETs and Notch signaling in ER+ breast cancer.
Endocrine tumor disorders
Dr. Konstantin Dragnev is a medical oncologist in Lebanon, New Hampshire and is affiliated with Dartmouth-Hitchcock Medical Center. He received his medical degree from Medical University of Sofia FOM and has been in practice for more than 20 years.
Medical oncology/ hematology; aerodigestive tract cancer; lung cancer; brain metastases
Mirco Fanelli is Associate Professor of Technical Sciences of Laboratory Medicine at the University of Urbino, He graduated in Biological Sciences at the University of Camerino in 1994. He obtained in 1996 a PhD position at the European Institute of Oncology (Milan, Italy) and contributed to the understanding of molecular basis of the leukemogenesis (APL model). In the last years his research activity was focused in two important fields: 1) the development of new experimental strategies (PAT-ChIP) that can allow the identification of epigenetic profile of cancer in complex biological models (e.g. FFPE-tissues, microdissected samples, etc.); 2) the identification and characterization of new synthetic compounds able to interfere with the chromatin structure with the aim to develop novel therapeutic strategies against cancer.
Glioblastoma; liver cancer; breast cancer; cancer epigenetics, PAT-ChIP, cancer treatment
Minoru Fukuda is Department Head of Chemotherapy at Nagasaki University Hospital, and Vice General Manager and Associate Professor of Nagasaki University Clinical Oncology Center. He is councilor and publicity member of Japanese Society of Clinical Oncology, and councilor and guideline member of Japan Lung Cancer Society.
Lung cancer; lung adenocarcinoma
Dr. Brunilde Gril is a staff scientist in the Women’s Malignancies Branch, Center for Cancer Research, NCI, USA. Prior to joining NCI, Dr. Gril received her PhD in Molecular Pharmacology in 2006, from the University of Paris René Descartes, France. Dr. Gril has worked for more than ten years on translational research investigating brain metastases of breast cancer with a multifocal approach. The overarching theme of her research involves identifying molecular targets, determining mechanism of action, deciphering signaling pathways, and preclinical testing of developmental therapeutics in mouse models of brain metastases of breast cancer. Since four years, Dr. Gril focused her research on the investigation of the molecular underpinnings of altered blood-brain barrier permeability, in order to eventually develop strategies to improve drug uptake. She received several awards from different organizations such as AACR and ASCO, and received the NCI Director’s Intramural Innovation Award in 2012.
Tumor cell signaling pathways to identify oncology targets and biomarkers; tumor microenvironment; molecular basis for experimental therapeutics and translational study; brain metastatic breast cancer; Her-2; VEGFR and EGFR signal pathway; blood-tumor barrier and blood-brain barrier
Dr Egidio Iorio is a Researcher of Department of Cell Biology and Neurosciences at the Istituto Superiore di Sanità (Rome- Italy). Master Degree in Biological Sciences and Specialization in Clinical Pathology at University of Rome "La Sapienza". PhD in Biochemistry and Molecular Biology at University of Rome "Tor Vergata". The main research interests of Dr Iorio were focused on alterations in metabolism in relation to cell differentiation, tumor growth and cell death. He is actively involved in projects to develop original molecular imaging methods for the identifications of magnetic resonance spectroscopy biomarkers of tumour cell proliferation and response to therapy.
Biochemistry; magnetic resonance spectroscopy; metabolomic; lipid and glucose metabolism; cell signaling.
Gary Li has nearly 20 years’ experience in biomedical research and pharmaceutical research and development. He is currently Executive Director, overseeing all discovery and translational research efforts at Ignyta, Inc., a clinical-stage, precision oncology company located in San Diego, California. Before joining Ignyta, Gary spent 10 years at Pfizer and 1 year at Johnson & Johnson, playing multiple key roles in cancer research and drug discovery with increasing responsibilities. Gary obtained his Ph.D. from the University of Pennsylvania, School of Medicine in 2003. He holds multiple patents and has published over 40 peer-reviewed articles in top science and medical journals and delivered over 60 invited talks and meeting presentations.
Cancer biology and therapeutics
cancer genomics; pharmacology; biomarkers; resistance; drug discovery; translational research; melanoma; translational oncology
Dr. Shuen-Kuei Liao earned his PhD degree from McMaster University, Canada, and subsequently received his postdoctoral training at University of Toronto. He has been working in the areas of cancer biology and immunotherapy in Canada, USA and Taiwan over the past three decades. Currently he is Professor at Taipei Medical University with his interests in cancer stem cells and immunotherapy, and the roles of mesenchymal stem cells in transplantation.
Cancer biology and immunology; immunotherapy for cancer; melanoma; retinoblastoma, glioblastoma; germ cell tumor metastatasis and treatment
Dr. Silvana Morello is Research Scientist in Pharmacology at the Department of Pharmacy, University of Salerno, Italy. She obtained a PhD in Science of Drug at the University of Naples “Federico II”, Italy. She was an academic visitor at the Medical School of the University of Sherbrooke (Québec), Canada in 2000 and at the National Heart and Lung Institute of the Imperial College of London, UK in 2003-2004 She is currently Professor of Immunopharmacology and Clinic Pharmacology at the Department of Pharmacy, University of Salerno, Italy.
Cancer biology and immunology; Cancer immunotherapy; melanoma.
Dr. Mohamed I. Nounou serves the Appalachian College of Pharmacy (Oakwood, VA, USA) as an assistant professor of pharmaceutical sciences. His current research is focused on brain drug delivery, non-viral gene delivery, weight loss management, topical and transdermal drug delivery and quality of pharmaceuticals, nutraceuticals and cosmeceuticals.
Brain drug delivery; non-viral gene delivery; weight loss management; topical and transdermal drug delivery and quality of pharmaceuticals, nutraceuticals and cosmeceuticals
Dr. Pravin D. Potdar's present interest is to study molecular profiling of Circulating Tumor Cells (CTC), Circulating Tumor DNA, Cancer Associated Fibroblasts and Cancer Stem Cells involved in metastatic process of cancers, and to see how this process can be reverted back to normal by using innovated technologies which include nanotechnology and nanomedicine.
Cancer stem cells & therapy; molecular diagnostics for cancer ; infectious diseases; neurological and genetic disorders; early detection markers for breast and lung cancer; molecular targeted therapies of cancer
Dr Stephen J. Ralph: Sole inventor on two full patents, and co-inventor on two additional provisional patent applications - 4 patents based on his research outputs covering cancer vaccines, improved immune adjuvants to enhance the potency of vaccines and design of novel anticancer drugs has meant that the research is well positioned now with secure Intellectual Property ready for commercialisation.. These patents will all become full national phase by the end of 2010. Show a continual history of major federal, state and local competitive grant funding success starting at Monash and continuing at Griffith University, as lead CIA on 2 NHMRC grants, a Queensland Cancer Council grant, and CIB on a QCC grant, ARC project grants, a prestigious National Breast Cancer Foundation, Kathleen Cunningham grant. Total State and Fed. grant funds in excess of $1million, excluding $300,000 in GURIP and GURG internal Griffith University grants for funding to purchase an ultrasound machine for use on small animals. Currently applying to ARC LIEF in a bid for a micro CT scanner as well as a light based imaging machine for small animals. Dr Ralph has successfully attracted large research investments from pharmaceutical companies and private investors repeatedly for his laboratory to develop cancer vaccines and novel cancer therapies with net worth of over $2.5 million over the last 10 years. After many presentations to CM Capital, Uniseed, Cancervax, Glycoz, Serono, Avastra, Biotech Capital, Starfish, GB investments and others including QLD State Govt, in late 2003, successfully secured funding from the pre-seed capital fund, SciVentures, to enable development of cancer vaccine formulation into phase I clinical trials and obtained SPIRT grant (equivalent of ARC Linkage grant). However, SciVentures withdrew support in 2004 and SPIRT grant had to be relinquished. In July 2004, in collaboration with Prof. Grant McArthur at the Peter MacCallum Cancer Research Institute in Melbourne, a grant of ~ $25,000 was obtained from Schering Plough Pty Ltd. to undertake a retrospective clinical study of archival melanoma patient responses to interferon therapy. This successfully showed that expression of two biomarkers in clinical samples provided excellent predictors of patient responses to interferon therapy and this represents a very significant advance in the use of interferons as a drug. Invited speaker at the EMBO meeting on Mitochondria and Cancer “MAC 09” in Prague in 2009 and chaired a session. As scientific director of Genvax Pty Ltd, involved in managing the research and development of cancer vaccines, having obtained ethics for a Therapeutics Goods Administration Australia registered Phase I clinical trial presently proceeding at the Princess Alexandra Hospital, Brisbane, since early 2009. Currently a consultant to Australian Botanical Biosciences Pty Ltd (now Active 98 Pty ltd) involved in developing Australian tea tree oil based products as anticancer drugs, now in clinical trial. Visiting Research Fellowship applied for and obtained for collaborator, Prof. Rafael Moreno-Sanchez, from Mexico in 2009 as an expert helping to identify target sites in the mitochondrial respiratory chain for the MITOCAN, alpha tocopheryl succinate. This collaboration has proved extremely successful.
Metastatic malignancy; relationships to the immune system and mechanisms for promoting metastasis; the relevance of hypoxia and galectin expression as a trigger for the process within the tumor micronenvironment;menaloma; lung metastasis; anticancer drug
Palma Rocchi received her PhD in 2002 from the Medicine Faculty of Marseille evaluating the molecular mechanisms involved in the castration-resistant prostate cancer (CRPC). In her three years as post-doctoral fellow in the University of British Columbia Prostate Centre in Dr Gleave’s Lab. Palma Rocchi completed her formation by receiving advance training in targeting genes associated with CR and treatment resistance in PC. She developed a drug (OGX-427) using oligonucleotide antisens and siRNA approach able to significantly dose-dependent down-regulate Hsp27 protein expression level. OGX-427 has been patented and obtained an international license by the University of British Columbia and Oncogenex and clinical trials phase II is now in process in Canada and United States to evaluate the effect of OGX-427 in patients with PC and other solid tumors like breast, ovarian, bladder, prostate and lung cancer. She has now completed her post-doctoral fellowship and found a position as an independent senior investigator in PC translational research at the French National Institute for Health and Medical Research. She is now leading a research group on translational research to improve treatment resistance in PC. Her principal research interest is focused drug discovery for the treatment of CRPC.
Drug discovery for the treatment of castration-resistant prostate cancer; celltherapy metastatic prostate cancer
Dr. Saleh is a Consultant of Clinical Biochemistry and Ass. Professor of Cancer Biology at the Faculty of Medicine, Umm Al Qura University (UQU), Saudi Arabia. He previously worked at the Oncology Diagnostic Unit, Faculty of Medicine, Ain Shams University, Egypt.
Dr. Saleh is an Advisor for Vice Presidency for Business & Innovation at UQU and he has overall responsibility for international collaboration.
Dr Saleh’s technical expertise including state of the art cellular and molecular methods, such as qPCR; protein purification; western blot; Flow Cytometry and FACS; Protein Sequencing techniques; ELISA and CLIA. In addition to ICP-MS and HPLC.
Dr. Saleh is a member of American Association of Clinical Chemistry [AACC]; American Society for Biochemistry and Molecular Biology [ASBMB]; The Egyptian Society of Biochemistry and Molecular Biology; and The Egyptian Society for Tumor Markers Oncology.
Diagnostic oncology; prostate cancer; bladder cancer
Prof. Dr. Nedime Serakıncı was born in Nicosia in 1970. She completed her undergraduate biology degree in İstanbul University in 1992. She received her Master’s degree at Division of Internal Medicine, Çapa Faculty of Medicine, Istanbul University in 1993 and continued onto Faculty of Medicine with a special student status. She completed her first PhD at Department of Medical Biology and Genetics in Marmara University. Through her research on telomere-telomerase biology, cancer and stem cell biology, With the funding she received for various projects, she established ‘Stem cell and Genetic Therapy’ research program within the Institute of Human Genetics at Aarhus University.
Besides medical genetics, Prof. Serakıncı also works on and interested in mesechymal stem cell biology, cancer and telomere/telomerase biology. In 2003, she became an associate professor in the field of Medical genetics and received another associate professorship in her second field of interest, aging and stem cell genetics, in 2007. She received professorship in the fields of medical genetics and stem cell genetics in 2011.
Her research expertise is in telomerase-immortalized mesenchymal stem cells and their use in genetic therapy and development of tissue models for drug discovery.
Prof. Dr Serakıncı’s research program is focused on the molecular, cellular and developmental biology of the adult mesenchymal stem cell. The principle aim of the program is to develop strategic and technical approaches necessary to acquire an understanding of the mechanisms underlying stem cell self-renewal and differentiation processes. Ultimately the objective is to provide rational scientific foundations for the application of cell and gene based therapies to the treatment of human disease and injury.
mesenchymal stem cells; telomere/telomerase biology; Genetics and cancer diagnosis; leukemia
Qiang Shen, MD, PhD, is an Assistant Professor in the Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences at the University of Texas M. D. Anderson Cancer Center. He earned his PhD in Cell Biology from The University of Texas Medical Branch at Galveston in 2001. Dr. Shen then did a postdoc with Dr. Powel Brown at Baylor College of Medicine, Lester and Sue Smith Breast Center till 2006 and was then promoted to Instructor in the Departments of Medicine and Cellular & Molecular Biology. Dr. Shen joined the Department of Clinical Cancer Prevention at M.D. Anderson Cancer Center in 2009. Dr. Shen’s current research focuses on elucidating the mechanisms by which normal pancreatic and mammary cells are malignantly transformed into cancer cells. He is interested in identifying novel targets for the prevention and treatment of pancreatic and breast cancer. More specifically, Dr. Shen studies the activation of transcription factors, kinases, and ion channels in normal and cancer cells; using molecular, cellular and transgenic approaches. In addition, Dr. Shen recently obtained an NIH/NCI K22 Award to conduct a study on the AP-1 transcription factor in breast cancer metastasis.
Activation of transcription factors; kinases; and ion channels in normal and cancer cells; using molecular; cellular and transgenic approaches.
Dr. Siddiqui earned his BSc and MSc degrees in Biochemistry from the University of Karachi, in Karachi, Pakistan. He obtained his PhD from the Australian National University in Canberra, Australia. While obtaining his PhD, he investigated the metabolic basis of cancer cachexia under the supervision of Professor John F. Williams, who is famous for his pioneer research on the pentose phosphate pathway. Dr. Siddiqui served as a postdoctoral fellow at Massey University in Palmerton North, New Zealand in the laboratory of Dr. Stuart McCutcheon (currently Vice Chancellor of Auckland University in New Zealand). Dr. Siddiqui immigrated to America in 1989 and worked as a Howard Hughes fellowship at Vanderbilt University Medical Center in Nashville with Dr. John Exton. Dr. Siddiqui began his work as a researcher at Methodist Hospital in 1993 in the Bone Marrow Transplant Research Laboratory. He established his independent research laboratory in 1999 and is presently the Senior Investigator and Director of the Cellular Biochemistry Research Laboratory at the Methodist Research Institute. Dr. Siddiqui also has adjunct appointments in the Department of Biology, Indiana University-Purdue University and the Department of Medicine, Indiana University Medical School, Indianapolis. Dr. Siddiqui has received funding from the National Cancer Center (NIH), American Heart Association, Showalter Foundation, Abbott Pharmaceuticals, and Baxter Nutrition.
Kinase inhibitors; cancer biology; brain tumors and metastasis
Dr. Ira-Ida Skvortsova studied medicine at the Altai State Medical University (Russia) from 1981-1987. She completed her oncology residency at the same University, as well as an ESMO research fellowship at Innsbruck Medical University (Austria). Since 2000, Dr. Skvortsova is a head of the Laboratory for Translational Research in Radiation Oncology (Dept. of Therapeutic Radiology and Oncology, Innsbruck Medical University).
Antonio Sommariva is Surgical Oncologist at the Surgical Oncology Unit of Istituto Oncologico Veneto where he is actively involved in the surgical care of cancer patients. He specialized in General Surgery at the University in Padova. He spent study periods at the following institutions (Jackson Memorial Hospital, Miami-USA, Royal Infirmary, Edinburgh-UK and MD Anderson Cancer Center, Houston-USA). He is member of European Society of Surgical Oncology-ESSO and the Italian Melanoma Intergroup-IMI. His clinical and research activity is mainly directed in melanoma, soft tissue sarcomas and peritoneal carcinomatosis. Currently he leads international clinical research projects on minimally invasive surgery techniques and quality control in surgical oncology. He is collaborator of the International Melanoma Database and Discovery Platform (IMDDP) and is involved as contributing data center for the next AJCC 8th edition melanoma staging system.
Melanoma and sarcoma; gastrointestinal oncology gastric cancer
Giovanni Tuccari was born in Messina 9 August 1955. He achieved the degree in Medicine and Surgery (points 110/110 cum laude) at the University of Pisa (31 October 1979). - Specialization in Anatomic Pathology (points 50/50 cum laude) at the University of Messina (23 July 1983). Associate professor of Pathology at University of Messina (25 May 1987). Full professor of Pathology at the University of Messina (14 March 2000). Vice-Chancellor at the University of Messina for Health's Questions (2013, until now). Reviewer and component of the scientific board of many journals. Member of many scientific Societies.
Cancer biology; colorectal cancer; cancer biomarkers; cancer diagnostics; cell Signaling
She is the head of the Glycoimmunology Research Group. She presently coordinates several multidisciplinary national and international projects in Glycosciences, involving clinical teams, as well as Biotech and Pharma companies and patient associations. Her focus is on Glycobiology, Oncobiology and Immunology projects with impact on cancer, infection and rare diseases. She is an Assistant Professor and director of the Congenital disorders of Glycosylation - Professionals and Patient Associations International Network(CDG & Allies - PPAIN).
Glycan alterations in cancer cells, immunotherapies, dendritic cell-based vaccines, antibodies, rare diseases
Prof. Zhou Wang is the Professor and UPMC Chair in Urological Research, Shadyside Medical Center, university of Pittsburgh. Prof. Wang’s lab is interested in the mechanism of androgen action and the roles of androgens in benign and cancerous prostate growth. The long-term objective of his research is to identify new targets for the treatment and prevention of prostate cancer and benign prostatic hyperplasia (BPH).
One area of research is to determine the role of androgen-responsive genes in the prostate. Prof. Wang’s lab recently showed that one of the androgen-responsive gene, U19/Eaf2, is a tumor suppressor. U19/Eaf2 downregulation and loss of heterozygosity were observed in more than 80% of advanced human prostate cancer specimens examined, indicating that Eaf2 likely blocks prostate cancer progression. Overexpression of Eaf2 induced apoptosis of prostate cancer cell lines, both in vitro and in vivo, while Eaf2 gene knockout in mice resulted in tumors in multiple tissues. These findings demonstrate that Eaf2 indeed functions as a tumor suppressor. His current research focuses on U19/Eaf2-binding partners and Eaf2-downstream genes to better understand U19/Eaf2 function in prostate carcinogenesis and to elucidate the mechanisms by which androgens can modulate prostate cancer progression.
Receptor Pharmacology; Drug Discovery; Cancer Pharmacology; Signal Transduction
Prof. Xie focuses on mechanisms underlying human disease, with the goal of improving patient care and outcomes. During graduate and postdoctoral training, he gained tremendous experience in molecular biology and expertise in utilizing various in vivo animal models. he also contributed to fields of study that resulted in frequently-cited publications, i.e., the novel role of zinc-finger protein and the ATM gene in cell fate determination and cell cycle checkpoints, respectively. His work with human colon cancer cells led to the seminal observation that muscarinic receptor activation stimulates expression of selected matrix metalloproteinases (i.e., MMP1, MMP7 and MMP10). Work supported by his NIH K08 award is focused on elucidating the role and mechanisms of MMP gene expression and activation in promoting colon neoplasia.
The role of matrix metalloproteinases in mediating farnesoid X receptor- and muscarinic receptor-dependent intestinal epithelial cell proliferation and colon neoplasia; esophageal motility disorders and colorectal cancer; internal medicine and gastroenterology; gastric cancer
Dr. Ren Xu is an Associated Professor at the Markey Cancer Center, University of Kentucky. Research in his group focuses on the biological function and regulation of ECM microenvironment in normal tissue and cancer development. His recent findings reveal the crucial function of cancer-cell derived-ECM in breast cancer progression.
Dr. Jin-Zhang Zeng received his B.S. (1989), M.S. (1995) and Ph.D. (1998) at First Military Medical University (Guangzhou, China). He continued his academic research at Second Military Medical University as a postdoctoral fellow, assistant professor and associate professor from 1998 through 2005 (Shanghai, China). After that, he worked as an associate professor (2005-2006) at Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and as a visiting scholar (2006-2007) at Sanford-Burnham Medical Research Institute (CA, La Jolla). In 2007, Dr. Zeng moved to Xiamen University (XMU) to set up his own laboratory as a Professor and acting director of Cancer Center at Institutes for Biomedical Research. From 2011 till now, Dr. Zeng is Professor and Deputy Dean of School of Pharmaceutical Sciences (XMU). He has published papers on top journals, including Cancer Res, Cancer Cell, Oncogene, FASEB J, PLoS ONE, Carcinogenesis, J Biol Chem, Anal Chem and Expert Opin Ther Targets. He is also a co-inventor of eight issued patents and a peer reviewer of Cancer Res, Carcinogenesis, Biochem Pharm, BMC Cancer, Genomics Proteomics and Bioinformatics, and Acta Pharmacol Sin. In recent years, he was awarded for more than ten research grants, including funding from National 863 Project, National Natural Science Foundation of China, NSFC/RGC project, Science and Technology Project of Fujian Province, Natural Science Foundation of Fujian Province, joint R&D projects.
Tumor biology; colon cancer; liver cancer
Prof. Bo Zhu is the Director and Professor at the Institute of Cancer, Xinqiao Hospital, Third Military Medical University. Dr. Zhu received his bachelor and doctoral degrees at the Third Military Medical University. He was trained as a postdoctoral at Queen Mary’s School of Medicine, London, UK. He is also a Chief Physician in Oncology. Dr. Zhu’s basic research and translational medical research mainly focuses on lung cancer immunology and immunotherapy. His work has been published on several renowned journals, such as J Exp Med, J Clin Invest, Clin Cancer Res, Stem Cells, Oncogene, Oncotarget, and so on. He has been actively involved in more than five clinical trials for non-small-cell lung carcinoma as center PI during last three years.
Tumor microenvironment, Tumor immunology and Immunotherapy